Design Therapeutics Company Leadership
| DSGN Stock | USD 4.69 0.11 2.29% |
Design Therapeutics employs about 54 people. The company is managed by 9 executives with a total tenure of roughly 126 years, averaging almost 14.0 years of service per executive, having 6.0 employees per reported executive. Analysis of Design Therapeutics' management performance can provide insight into the firm performance.
Insider Sentiment 50
Impartial
Selling | Buying |
Latest Trades
| 2024-12-18 | Deepa Prasad | Disposed 3806 @ 6.27 | View | ||
| 2024-08-09 | Arsani William | Disposed 814874 @ 4.25 | View | ||
| 2024-03-25 | John P Schmid | Acquired 17809 @ 3.74 | View | ||
| 2024-03-22 | John P Schmid | Acquired 9156 @ 3.62 | View |
Monitoring Design Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Design |
Design Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.1354) % which means that it has lost $0.1354 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1778) %, meaning that it created substantial loss on money invested by shareholders. Design Therapeutics' management efficiency ratios could be used to measure how well Design Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of February 2025, Return On Tangible Assets is likely to drop to -0.22. In addition to that, Return On Capital Employed is likely to grow to -0.31. At this time, Design Therapeutics' Other Current Assets are very stable compared to the past year. As of the 26th of February 2025, Asset Turnover is likely to grow to 0.000007, while Total Assets are likely to drop about 232.7 M.As of the 26th of February 2025, Common Stock Shares Outstanding is likely to drop to about 46.6 M. In addition to that, Net Loss is likely to grow to about (54.1 M)
Design Therapeutics Workforce Comparison
Design Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,268. Design Therapeutics holds roughly 54.0 in number of employees claiming about 2.38% of equities under Health Care industry.
Design Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Design Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Design Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Design Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 1.25 | 5 | 4 | 488,265 | 605,000 |
| 2022-03-01 | 6.0 | 6 | 1 | 1,386,806 | 13,200 |
| 2021-09-01 | 0.5 | 1 | 2 | 40,000 | 24,539 |
| 2021-03-01 | 1.2917 | 31 | 24 | 31,634,854 | 49,626,310 |
Design Therapeutics Notable Stakeholders
A Design Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Design Therapeutics often face trade-offs trying to please all of them. Design Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Design Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Pratik Shah | President CoFounder | Profile | |
| Aseem Ansari | CoFounder Advisor | Profile | |
| Sean Jeffries | Chief Officer | Profile | |
| Elizabeth Gordon | Senior Affairs | Profile | |
| Mustapha Parekh | General Counsel | Profile | |
| Joo MD | CEO Pres | Profile | |
| MD FACC | Consulting Officer | Profile | |
| Dawn Giangiulio | Controller | Profile | |
| Julie CPA | Chief Officer | Profile |
About Design Therapeutics Management Performance
The success or failure of an entity such as Design Therapeutics often depends on how effective the management is. Design Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Design management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Design management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.32) | (0.31) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.28) | (0.26) |
Design Therapeutics Workforce Analysis
Traditionally, organizations such as Design Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Design Therapeutics within its industry.Design Therapeutics Manpower Efficiency
Return on Design Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 7.4M | |
| Working Capital Per Employee | 5.1M | |
| Working Capital Per Executive | 30.6M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Design Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.